SAN DIEGO, Nov. 4, 2014 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive
management team as Chief Legal Officer.
"We are very pleased to welcome Darin
Lippoldt to the Neurocrine leadership team as our Chief
Legal Officer," said Kevin Gorman,
President and Chief Executive Officer of Neurocrine Biosciences.
"Darin's breadth of experience in both developmental and commercial
biotechnology companies will be of critical importance as
Neurocrine evolves into a fully-integrated pharmaceutical
company."
Prior to joining Neurocrine, Mr. Lippoldt served as Executive
Vice President and General Counsel of Volcano Corporation, a
company he joined in 2010. Prior to Volcano, Mr. Lippoldt served as
Associate General Counsel at Amylin Pharmaceuticals, Inc. since
2003. He previously practiced corporate and securities law with the
law firms of Fulbright & Jaworski LLP and Matthews and
Branscomb, P.C. Mr. Lippoldt received a B.B.A. in Finance, an M.A.
in International Relations, and a J.D. from St
Mary's University.
Neurocrine also announced the grant of an inducement award to
Mr. Lippoldt pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Rules in connection with his employment with Neurocrine. In
connection with the employment agreement, Mr. Lippoldt was granted
an inducement award consisting of a stock option to purchase 95,000
shares of Neurocrine common stock. The stock option will vest over
a period of four years, with 25% vesting on the first anniversary
of the grant date and the balance vesting each month over the
remaining three years. This award is subject to the terms and
conditions of Neurocrine's Inducement Plan. This award was
effective on November 3, 2014, the
first business day of the first calendar month following the
commencement of his employment with Neurocrine, and has an exercise
price of $18.15 per share, which was
the closing price of Neurocrine's common stock on the NASDAQ Global
Select Market on that date. The award was granted as an inducement
material to Mr. Lippoldt's employment pursuant to Rule 5635(c)(4)
of the NASDAQ Listing Rules.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and a wholly owned vesicular
monoamine transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial rights
to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company. Neurocrine Biosciences, Inc. news
releases are available through the Company's website via the
internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.